Merck and Moderna's mRNA Cancer Vaccine Shows Promise in Phase 3 Trials
Merck and Moderna's mRNA-based cancer vaccine for melanoma shows strong Phase 3 trial results, signaling a shift in cancer therapy.
Eli Lilly's FDA Approval: A Game Changer for Alzheimer's Diagnostics
Eli Lilly's recent FDA approval for an Alzheimer's blood test signals a pivotal moment in diagnostics, impacting investors and patients alike.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Booz Allen Hamilton Strengthens Defense Sector with Ultra I&C Acquisition
Booz Allen Hamilton (BAH) completes acquisition of Ultra I&C, bolstering its defense technology capabilities amid growin…
Merck and Moderna's Phase 3 Success: A Milestone in Cancer Vaccination
Merck and Moderna report significant success in their Phase 3 trial, reinforcing the role of KEYTRUDA in oncology.
Eli Lilly's FDA Approval: A Game Changer for Alzheimer's Diagnostics
Eli Lilly's FDA approval for an Alzheimer's blood test could reshape the diagnostics landscape and boost investor sentim…
TG Therapeutics on the Rise: Exploring the Potential of Takeover Speculation
TG Therapeutics gains traction amid takeover rumors, reflecting broader M&A interest in the pharmaceutical sector.
Impact of U.S.-Canada Trade Talks Collapse on Market Dynamics: What Investors Need to Know
The collapse of U.S.-Canada trade talks and new tariffs raise concerns for investors. Here's what you need to know.
Moderna's Cancer Vaccine Breakthrough: Implications for Investors and Biotech Traders
The recent Phase 3 trial results for Moderna's cancer vaccine have sent shockwaves through the biotech sector, raising i…
Bunker Hill Mining and Silver47 Merger: A New Player in Critical Minerals
Bunker Hill Mining and Silver47 Exploration unite in a $163M all-stock deal, reshaping the critical minerals landscape.
Capricor Therapeutics Faces PDUFA Date: What Investors Should Know
Capricor's stock dropped nearly 8% as it awaits an FDA decision on Deramiocel for Duchenne muscular dystrophy.
Moderna's Cancer Vaccine Triumph: What This Means for Investors
Moderna's stock surged 176.97% after successful Phase 3 trial results for its cancer vaccine, signaling potential market…